Eli Lilly & Co. is planning to submit positive new Phase III data for abemaciclib in high-risk breast cancer to regulatory authorities by the end of the year, after the monarchE trial showed significant improvement in invasive disease-free survival in conjunction with endocrine therapy.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?